Drug Profile


Alternative Names: FGFRRx; IONIS-FGFR4Rx; ISIS 463588; ISIS-FGFR4Rx; ISIS-FGFRRx

Latest Information Update: 14 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator The University of Queensland
  • Developer Ionis Pharmaceuticals
  • Class Antisense oligonucleotides; Obesity therapies
  • Mechanism of Action Type 4 fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Obesity

Most Recent Events

  • 01 Sep 2016 Ionis Pharmaceuticals completes the FGFR4-CS2 trial in Obesity in USA (SC) (NCT02476019)
  • 18 Dec 2015 Isis Pharmaceuticals is now called Ionis Pharmaceuticals
  • 10 Jun 2015 Translational Research Institute for Metabolism and Diabetes plans a phase IIa trial in Obesity in USA (NCT02463240)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top